EBNA1 Antibody (0211 (6F9/60))

Product Discontinued

EBNA1 Antibody (0211 (6F9/60)) Summary

• Immunogen: Made to EBNA1
• Specificity: NB100-66642 is specific for Epstein-Barr virus nuclear antigen 1 (EBNA1), a viral protein required to maintain the EBV genomes in proflierating cells. It fulfils this role by binding to recognition sites in the FR and DS elements of the latent origin of DNA replication (oriP) within the episome. This promotes DNA replication and is involved with the partitioning of the episome during cell division and the activation of other viral latency genes. EBNA1 is able to avoid detection by cytotoxic T-lymphocytes which enables the persistence of latently infected cells that express EBNA1 in the absence of other EBV antigens.
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation 1:10-1:500
  • Western Blot 1:100-1:2000

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.1% Sodium Azide
• Concentration: 0.1 mg/ml
• Purity: Protein A purified

Alternate Names for EBNA1 Antibody (0211 (6F9/60))

• BKRF1
• Epstein-Barr nuclear antigen 1
• HHV4gp098
• nuclear antigen EBNA1

Background

Epstein Barr virus (EBV) is a member of the herpesvirus family and one of the most common human viruses. Most people become infected with EBV during their lives. Primary infections usually results in infectious mononucleosis (glandular fever) but the virus can also lay dormant in B lymphocytes and when reactivated become associated with more serious disease such as Burkitt's lymphoma, nasopharyngeal carcinoma and Hodgkin's disease.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for EBNA1 Antibody (NB100-66642)(3)

Publications using NB100-66642

• Satake T Epstein-Barr virus-based plasmid enables inheritable transgene expression in mouse cerebral cortex PLOS ONE 2021-09-30 [PMID: 34591902] (ICC/IF)
• Montgomery ND, Randall C, Painschab M et al. High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi Cancer Med 2020-01-01 [PMID: 31782984] (IF/IHC, Human)
• Cao P, Zhang M, Wang L et al. miR-18a reactivates the Epstein-Barr virus through defective DNA damage response and promotes genomic instability in EBV-associated lymphomas BMC Cancer 2018-12-29 [PMID: 30594162] (IF/IHC, Human)

FAQs for EBNA1 Antibody (NB100-66642). (Showing 1 - 1 of 1 FAQs).

1. As a pathologist with a great deal of experience in immunohistochemistry and a long-standing research/diagnostic interest in EBV, I would be very interested in trying out your EBNA-1 antibody on a variety of EBV-positive FFPE human biopsy tissues. Assuming I can get good staining with your antibody, I will be happy to provide you with the staining protocol and several good images you can post on your website. Can you provide me some antibody to try out?
   • We highly appreciate your request and but I am really sorry as we would not be able to offer free samples of EBNA-1 antibodies at the moment. Our EBNA-1 antibody (0211 (6F9/60)) (NB100-66642) is well established and is useful for IHC-P as well. However, there are couple of other options also that you may find interesting. (1) Have you heard of our Innovators Reward Program? Under this program, if someone tests an antibody in an untested species/application and share results with us, Novus provides a 50% refund on the purchased product as well as a 50% discount on a future product of equal value in exchange for new data. EBNA1 Antibody (E1-2.5) (NB500-312) would be a good option if you wish to try our Innovators Reward program (2) It would be an honor to for us to collaborate with you on our projects involving our new antibodies. From time to time, I personally work on projects in which we send samples of newly launched antibodies to researchers with extensive expertise in a particular area for validation testing in different applications/species. If you let me know more about your other ongoing projects and current research interests, I can definitely look into our current new targets to see if we can work on any targets! Please let me know if this is something you are interested in?